NAF1

NAF1 rs7675998 — The Telomere Assembly Variant That Trades Cancer Risk for Heart Protection

Deep inside your cells, telomeres serve as protective caps on chromosome ends — structural buffers that are consumed a little with each cell division. Maintaining them requires telomerase, a molecular machine with two essential parts: TERT, the protein enzyme, and TERC, the RNA template. But TERC cannot simply exist on its own. It must be folded, stabilized, and assembled into a functional complex. That assembly work is done by NAF1 — Nuclear Assembly Factor 1.

NAF1 acts as a chaperone for H/ACA box ribonucleoproteins (RNPs), a family of RNA-protein complexes that includes TERC. Without NAF1, TERC levels fall, telomerase activity declines, and telomeres shorten
more rapidly with each cell division. The rs7675998 variant at chromosome 4q32.2 sits approximately 40 kilobases upstream of the NAF1 transcription start site and acts as a regulatory eQTL — influencing how much NAF1 protein is produced and, downstream, how efficiently TERC is assembled and telomeres are maintained.

The Mechanism

NAF1 is an essential co-chaperone in the H/ACA RNP assembly pathway. The H/ACA box family of small nucleolar RNAs (snoRNAs) includes TERC, the RNA subunit of telomerase. For H/ACA RNAs to become functional, they must be bound by a set of core proteins — including dyskerin (NAP57), GAR1, NHP2, and NOP10 — in a precise, ordered process. NAF1 participates in the early steps of this assembly, loading newly transcribed H/ACA RNAs with the core trimer and later handing off to GAR1 for maturation.

Studies in both yeast and human cells confirm that reducing NAF1 levels directly reduces steady-state TERC levels and impairs telomerase activity, even without changing the TERC gene itself. In heterozygous Naf1+/− mice, TERC levels fell by approximately half. The rs7675998 A allele is associated with lower NAF1 expression (it is an eQTL in multiple tissues), leading to less efficient TERC biogenesis, lower telomerase activity, and shorter leukocyte telomere length over time.

This is a fundamentally different mechanism from TERC rs12696304, which sits in a TERC regulatory region, or TERT rs2736100, which affects the catalytic protein component. rs7675998 acts upstream — reducing the supply of functional telomerase RNA rather than disrupting the RNA or enzyme directly.

The Evidence

The landmark evidence came from a 2013 genome-wide association meta-analysis of 37,684 individuals by Codd et al. (Nature Genetics 2013), which identified seven loci associated with mean leukocyte telomere length at genome-wide significance (P < 5×10⁻⁸). The NAF1 locus at 4q32.2 (lead SNP rs7675998) was one of four newly identified loci, with the A allele associated with a beta of −0.074 standard deviations of telomere length per allele copy. This effect size is modest at the individual level but equivalent to roughly one to two years of age-related telomere attrition.

Crucially, the functional significance of this locus was validated by the convergence of two lines of evidence: the GWAS association with telomere length in blood, and the identification of NAF1 as a gene with a known, direct role in TERC biogenesis. Unlike purely intergenic signals, the NAF1 locus has a mechanistically coherent explanation.

In a Han Chinese cohort of 652 CHD patients and 648 controls, Li et al. (2014) found that the A allele of rs7675998 was the most strongly associated of seven telomere SNPs with coronary heart disease risk, with an odds ratio of 2.127 (95% CI 1.909–2.370). AA homozygotes developed CHD a mean of 6.9 years earlier than GG homozygotes (52.6±10.4 vs 59.5±9.2 years, P=0.012). This is consistent with the broader Mendelian randomization literature showing that genetically shorter telomeres increase cardiovascular disease risk.

A comprehensive Mendelian randomization study by Haycock et al. (JAMA Oncology 2017), using rs7675998 among its instrument SNPs, quantified the bidirectional consequences of telomere length across 35 diseases. Genetically longer telomeres (G allele direction) were protective for coronary heart disease (OR 0.78), interstitial lung disease (OR 0.09), abdominal aortic aneurysm (OR 0.63), celiac disease (OR 0.42), and Alzheimer's disease (OR 0.84). However, the same genetically longer telomere instrument was associated with substantially increased risk for glioma (OR 5.27), lung adenocarcinoma (OR 3.19), melanoma (OR 1.87), and other cancers.

This paradox — shorter telomeres harm the heart, longer telomeres favor cancer — reflects a fundamental evolutionary trade-off in telomere biology: cellular senescence protects against tumor formation but accelerates age-related organ failure. Carriers of the shorter-telomere A allele sit on one side of this trade-off.

Practical Implications

The A allele at rs7675998 is not a pathogenic mutation — it is a common variant that modestly shifts the balance of this biological trade-off. The A allele frequency in Europeans is approximately 22%, making the AG genotype the most common (~34% of the population). Only about 5% of Europeans are AA homozygotes.

For A-allele carriers, the practical concern is accelerated telomere shortening compounding with lifestyle factors that further erode telomere length — particularly smoking, chronic psychological stress, and excess adiposity, all of which have independent telomere-shortening effects that add to the genetic baseline.

Interactions

rs7675998 tags the NAF1 locus, which is mechanistically upstream of TERC and TERT. Individuals who also carry the risk allele at TERC rs12696304 (G allele, chromosome 3q26) or TERT rs2736100 (A allele, chromosome 5p15.33) have additional independent reductions in telomere maintenance capacity from different parts of the telomere-extension machinery. A genetic risk score combining multiple telomere loci predicts telomere length better than any single variant.

rs4691896 and rs936562, both in NAF1, are in strong linkage disequilibrium with rs7675998 (D' >0.7) and likely tag the same functional signal; they have been studied in the context of coal workers' pneumoconiosis and related lung disease.